Log in to save to my catalogue

Benralizumab for eosinophilic granulomatosis with polyangiitis

Benralizumab for eosinophilic granulomatosis with polyangiitis

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04205873v1

Benralizumab for eosinophilic granulomatosis with polyangiitis

About this item

Full title

Benralizumab for eosinophilic granulomatosis with polyangiitis

Publisher

England: BMJ Publishing Group Ltd and European League Against Rheumatism

Journal title

Annals of the rheumatic diseases, 2023-12, Vol.82 (12), p.1580-1586

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd and European League Against Rheumatism

More information

Scope and Contents

Contents

BackgroundBenralizumab is effective in the treatment of eosinophilic asthma and is being investigated for the treatment of other eosinophil-associated diseases. Reports on the use of benralizumab for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) are limited to case reports and small case series.MethodsWe conducted a multicen...

Alternative Titles

Full title

Benralizumab for eosinophilic granulomatosis with polyangiitis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_04205873v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04205873v1

Other Identifiers

ISSN

0003-4967

E-ISSN

1468-2060

DOI

10.1136/ard-2023-224624

How to access this item